Infectious Diseases Unit, Monash Children s Hospital, Melbourne, Australia.
Euro Surveill. 2012 Apr 19;17(16):20148.
The National Immunisation Program Schedule in Australia is formulated and funded nationally under the population-wide Medicare system. The policy is implemented by the eight state and territory jurisdictions. The national immunisation registers consist of the Australian Childhood Immunisation Register (ACIR), and, more recently, the National Human Papillomavirus (HPV) Vaccination Program Register. Moreover, a variety of jurisdiction-based registers and primary care practice software systems exist, which interact with the national registers. General practitioners can obtain reports listing patients under seven years attending their practice and recorded as 'not fully immunised', and immunisation coverage rates for their practice linked to government incentives through Medicare. A 2011 report documents national coverage of 91.8% fully immunised at 12 months, and 92.6% at 24 months. The HPV register provides information on vaccination coverage with the potential to link with a register of cervical cancer screening results. Limitations of current national register include inability to easily access immunisation histories beyond seven years of age, and issues of underreporting and timeliness, which impact significantly the immunisation coverage estimates. The linkage of these registers with healthcare outcome data will further enhance public health outcomes by enabling rapid, population-level vaccine safety and effectiveness investigations in a nation with a track record as an 'early adopter' of new childhood vaccines.
澳大利亚的国家免疫计划时间表是在全民医疗保险制度下由国家制定和资助的。该政策由八个州和地区司法管辖区执行。国家免疫登记册包括澳大利亚儿童免疫登记册(ACIR),以及最近的国家人乳头瘤病毒(HPV)疫苗接种计划登记册。此外,还存在各种基于司法管辖区的登记册和初级保健实践软件系统,它们与国家登记册相互作用。全科医生可以获得列出其诊所中未满 7 岁且被记录为“未完全免疫”的患者的报告,并通过医疗保险与政府激励措施挂钩,了解其诊所的免疫接种覆盖率。2011 年的一份报告记录了全国 12 个月时 91.8%的完全免疫覆盖率和 24 个月时 92.6%的完全免疫覆盖率。HPV 登记册提供了疫苗接种覆盖率的信息,有可能与宫颈癌筛查结果登记册相联系。当前国家登记册的局限性包括难以轻松获取 7 岁以上的免疫史,以及报告不足和及时性问题,这对免疫接种覆盖率估计有重大影响。这些登记册与医疗保健结果数据的联系将通过在一个具有记录的“早期采用者”新儿童疫苗的国家中进行快速的、基于人群的疫苗安全性和有效性调查,进一步增强公共卫生结果。